Cyrus J. Lawrence LLC Trims Stake in Roche Holding AG (OTCMKTS:RHHBY)

Cyrus J. Lawrence LLC reduced its position in Roche Holding AG (OTCMKTS:RHHBYFree Report) by 2.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,010 shares of the company’s stock after selling 400 shares during the period. Cyrus J. Lawrence LLC’s holdings in Roche were worth $577,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Vestor Capital LLC acquired a new stake in Roche in the 2nd quarter worth approximately $44,000. First Horizon Advisors Inc. boosted its stake in Roche by 39.4% in the 3rd quarter. First Horizon Advisors Inc. now owns 1,724 shares of the company’s stock worth $58,000 after purchasing an additional 487 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Roche during the 1st quarter valued at approximately $103,000. Motco lifted its stake in Roche by 612.7% during the 3rd quarter. Motco now owns 4,426 shares of the company’s stock valued at $151,000 after acquiring an additional 3,805 shares during the period. Finally, Paradigm Asset Management Co. LLC lifted its stake in Roche by 18.4% during the 3rd quarter. Paradigm Asset Management Co. LLC now owns 5,151 shares of the company’s stock valued at $175,000 after acquiring an additional 800 shares during the period.

Roche Trading Up 0.7 %

Shares of OTCMKTS RHHBY traded up $0.21 during mid-day trading on Monday, reaching $32.31. The company’s stock had a trading volume of 2,876,600 shares, compared to its average volume of 1,929,586. The stock has a 50-day moving average of $35.55 and a two-hundred day moving average of $35.22. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 0.86. Roche Holding AG has a 1-year low of $31.77 and a 1-year high of $40.48.

Wall Street Analyst Weigh In

Separately, Morgan Stanley lowered shares of Roche from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to, Roche has a consensus rating of “Hold” and a consensus price target of $40.00.

View Our Latest Stock Analysis on RHHBY

About Roche

(Free Report)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

Further Reading

Institutional Ownership by Quarter for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with's FREE daily email newsletter.